R. T. MacFarland

Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

Craig W. Hendrix, Charles Flexner, R. T. MacFarland et al. · Antimicrobial Agents and Chemotherapy · 2000 · 503 citations · Full text

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Craig W. Hendrix, Ann C. Collier, Michael M. Lederman et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 362 citations

Cxcr4 Receptor Inhibitor, Medicine, Antiviral Activity +14

High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.

R. T. MacFarland, Bruce D. Zelus, Joseph A. Beavo · Journal of Biological Chemistry · 1991 · 221 citations · Full text

High Concentrations, Cgs-pde Present, Glycobiology +26

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34 hematopoietic progenitor cells by AMD3100

Nathan A. Lack, B. Green, David C. Dale et al. · Clinical Pharmacology & Therapeutics · 2005 · 73 citations

CXCR4 antagonism as a therapeutic approach to prevent acute kidney injury

Anna Żuk, Michael Gershenovich, Yulia V. Ivanova et al. · American Journal of Physiology-Renal Physiology · 2014 · 44 citations